Thus the ability of ACE-inhibition and ARBs to counter this deleterious effect on the vascular phenotype could explain their beneficial effect, compared to other agents that decrease afterload, on morbidity and mortality in the treatment of heart failure. This evidence concerns the gene ACE and heart failure.